Zevra Stock Surges Close to 70% in 3 Months: Here's Why

Zacks10-04

Zevra Therapeutics, Inc. ZVRA obtained FDA approval for arimoclomol capsules for the treatment of Niemann-Pick disease type C (NPC) in September. The drug will be marketed under the brand name ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2473275962?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2","is_english":true,"pubTime":"2024-10-04 22:56","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2473275962","market":"us","top_or_hot":-1,"title":"Zevra Stock Surges Close to 70% in 3 Months: Here's Why","media":"Zacks","content":"<div>\n<p>Zevra Therapeutics, Inc. ZVRA obtained FDA approval for arimoclomol capsules for the treatment of Niemann-Pick disease type C (NPC) in September. The drug will be marketed under the brand name ...</p>\n\n<a href=\"https://finance.yahoo.com/news/zevra-stock-surges-close-70-145600184.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zevra Stock Surges Close to 70% in 3 Months: Here's Why</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZevra Stock Surges Close to 70% in 3 Months: Here's Why\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-04 22:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/zevra-stock-surges-close-70-145600184.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zevra Therapeutics, Inc. ZVRA obtained FDA approval for arimoclomol capsules for the treatment of Niemann-Pick disease type C (NPC) in September. The drug will be marketed under the brand name ...</p>\n\n<a href=\"https://finance.yahoo.com/news/zevra-stock-surges-close-70-145600184.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZVRA","symbol_name":"Zevra Therapeutics","start_time":0,"source_url":"https://finance.yahoo.com/news/zevra-stock-surges-close-70-145600184.html","article_id":"2473275962","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473275962","pubTimestamp":1728053760,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Zevra Therapeutics, Inc. ZVRA obtained FDA approval for arimoclomol capsules for the treatment of Niemann-Pick disease type C  in September. The drug will be marketed under the brand name Miplyffa.The FDA approved Miplyffa for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients aged two years and above.Following the FDA nod, Miplyffa became the first treatment to be approved for NPC, an ultra-rare and progressive neurodegenerative disease.Additionally, Zevra received a rare pediatric disease priority review voucher in conjunction with the FDA approval for Miplyffa.Shares of Zevra have surged 68.5% in the past three months compared with the industry’s rise of 9.3%.Zevra Therapeutics, Inc. price | Zevra Therapeutics, Inc. Quote. In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have moved up from $4.53 to $4.81. Earnings per share e","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZVRA":"Zevra Therapeutics","ANIP":"ANI Pharmaceuticals, Inc.","BK4139":"生物科技","FULC":"Fulcrum Therapeutics","BK4007":"制药","KRYS":"Krystal Biotech Inc."},"translate_title":"Zevra股价在3个月内飙升近70%：原因如下","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":1,"FULC":1,"KRYS":1,"ZVRA":0.9},"content_text":"Zevra Therapeutics, Inc. ZVRA obtained FDA approval for arimoclomol capsules for the treatment of Niemann-Pick disease type C (NPC) in September. The drug will be marketed under the brand name Miplyffa.\nThe FDA approved Miplyffa for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients aged two years and above.\nFollowing the FDA nod, Miplyffa became the first treatment to be approved for NPC, an ultra-rare and progressive neurodegenerative disease.\nAdditionally, Zevra received a rare pediatric disease priority review voucher in conjunction with the FDA approval for Miplyffa.\nShares of Zevra have surged 68.5% in the past three months compared with the industry’s rise of 9.3%.\nImage Source: Zacks Investment Research\nThe FDA approval for Miplyffa can be attributed as the reason for the stock price rally as the drug became the first approved treatment for this rare and devastating disease.\nNPC is an ultra-rare, progressive, and neurodegenerative lysosomal storage disorder characterized by an inability of the body to transport cholesterol and other lipids within the cell, leading to an accumulation of these substances in various tissues and organs, including the brain.\nZVRA's Miplyffa Approval Comes After Certain Setbacks\nThe approval of Miplyffa comes after a series of setbacks faced by Zevra previously.\nPlease note that the FDA extended the review period for the new drug application (NDA) for arimoclomol in March 2024. The NDA, resubmitted in December 2023, was originally assigned a target action date of June 21, 2024.\nThe FDA issued a complete response letter in June 2021 in response to the prior arimoclomol NDA filing. Hence, the NDA was resubmitted, including additional evidence supporting trial metrics, FDA-preferred analyses and data from multiple additional studies that provide supporting evidence of arimoclomol’s efficacy in clinical and non-clinical settings.\nIn August 2024, the FDA’s Genetic Metabolic Diseases Advisory Committee (GeMDAC) voted in favor of the data supporting arimoclomol as an effective treatment for NPC.\nThe NDA for arimoclomol was then assigned a target action date of Sept. 21, 2024.\nMiplyffa is likely to be launched in the United States in eight to 12 weeks following the FDA nod. The approval for Miplyffa should present a significant commercial opportunity for the company.\n\nZevra Therapeutics, Inc. Price\n  \nZevra Therapeutics, Inc. price | Zevra Therapeutics, Inc. Quote\n\nZVRA's Zacks Rank & Stocks to Consider\nZevra currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. ANIP, Krystal Biotech, Inc. KRYS and Fulcrum Therapeutics, Inc. FULC, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have moved up from $4.53 to $4.81. Earnings per share estimates for 2025 have improved from $5.38 to $5.86. Year to date, shares of ANIP have increased 3%.\nANIP’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.\nIn the past 60 days, estimates for Krystal Biotech’s 2024 earnings per share have increased from $1.91 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 41.8%.\nKRYS’ earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, with the average surprise being 45.95%.\nIn the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from 46 cents to 28 cents. Loss per share estimates for 2025 have narrowed from $1.67 to $1.14. Year to date, shares of FULC have plunged 45.7%.\nFULC’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 393.18%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report\nKrystal Biotech, Inc. (KRYS) : Free Stock Analysis Report\nFulcrum Therapeutics, Inc. (FULC) : Free Stock Analysis Report\nZevra Therapeutics, Inc. (ZVRA) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473275962"}